William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Key Points

• Director William Lis sold 8,506 Zai Lab shares at $25 each for $212,650, reducing his direct holdings by 16.86% to 41,931 shares. He also sold 7,040 shares in June.
• Zai Lab shares traded at $26.03, with a $2.96 billion market capitalization, after reporting a quarterly loss of $0.50 per share on $106.31 million in revenue. Analysts expect a full-year loss of $2.17 per share.
• Analyst sentiment remains a “Moderate Buy”, with an average price target of $40.20, while institutional investors and hedge funds own 41.65% of the company.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) Director William Lis sold 8,506 shares of Zai Lab stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the transaction, the director directly owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Lis also recently made the following trade(s):

• On Monday, June 22nd, William Lis sold 7,040 shares of Zai Lab stock. The stock was sold at an average price of $18.09, for a total transaction of $127,353.60.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB traded up $0.54 during midday trading on Thursday, reaching $26.03. The stock had a trading volume of 1,041,801 shares, compared to its average volume of 843,216. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -15.22 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $36.77. The stock has a 50-day moving average of $19.22 and a 200-day moving average of $19.39.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.The firm had revenue of $106.31 million during the quarter. As a group, analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZLAB has been the subject of several research analyst reports. Weiss Ratings upgraded Zai Lab from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Citigroup boosted their price target on Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Zacks Research upgraded Zai Lab from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Zai Lab from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Zai Lab has an average rating of "Moderate Buy" and an average target price of $40.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC increased its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,396 shares of the company's stock after buying an additional 642 shares during the period. SG Americas Securities LLC's holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

About Zai Lab

Zai Lab Ltd NASDAQ: ZLAB is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source